Skip to main content

Table 2 PET/CT characteristics according to neoadjuvant CRT regimen

From: Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen

 

Standard CRT

Extended CRT

p

Baseline SUVmax

21.5 ± 11.0

14.8 ± 5.9

0.004

6 weeks SUVmax

7.3 ± 6.3

1.9 ± 1.8

0.001

12 weeks SUVmax

8.4 ± 7.4

1.3 ± 1.9

0.001

Complete Response

18 (18.2 %)

8 (66.7 %)

0.001

∆ %SUVmax variation (6 weeks - baseline)

63.8 ± 24.1

88.1 ± 10.4

0.001

∆ %SUVmax variation (12 weeks - baseline)

57.9 ± 31.5

90.7 ± 13.0

0.001